The potential of antisense oligonucleotide therapies for inherited childhood lung diseases

Antisense oligonucleotides are an emerging therapeutic option to treat diseases with known genetic origin. In the age of personalised medicines, antisense oligonucleotides can sometimes be designed to target and bypass or overcome a patient’s genetic mutation, in particular those lesions that compromise normal pre-mRNA processing. Antisense oligonucleotides can alter gene expression through a variety of mechanisms as determined by the chemistry and antisense oligomer design. Through targeting the pre-mRNA, antisense oligonucleotides can alter splicing and induce a specific spliceoform or disrupt the reading frame, target an RNA transcript for degradation through RNaseH activation, block ribosome initiation of protein translation or disrupt miRNA function. The recent accelerated approval of eteplirsen (renamed Exondys 51™) by the Food and Drug Administration, for the treatment of Duchenne muscular dystrophy, and nusinersen, for the treatment of spinal muscular atrophy, herald a new and exciting era in splice-switching antisense oligonucleotide applications to treat inherited diseases. This review considers the potential of antisense oligonucleotides to treat inherited lung diseases of childhood with a focus on cystic fibrosis and disorders of surfactant protein metabolism.

[1]  Antisense oligonucleotides in cancer , 2014, Current opinion in oncology.

[2]  M. Welsh,et al.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.

[3]  R. Kole,et al.  Modification of alternative splicing by antisense therapeutics. , 2004, Oligonucleotides.

[4]  C. Lorson,et al.  A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Timothy Sterne-Weiler,et al.  Exon identity crisis: disease-causing mutations that disrupt the splicing code , 2014, Genome Biology.

[6]  C. Wallis,et al.  Ten‐year follow up of hydroxychloroquine treatment for ABCA3 deficiency , 2014, Pediatric pulmonology.

[7]  Thomas Jaki,et al.  A Bayesian adaptive design for clinical trials in rare diseases , 2016, Comput. Stat. Data Anal..

[8]  H. H. Choo,et al.  Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. , 2005, American journal of respiratory and critical care medicine.

[9]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[10]  J. McDonald,et al.  Local and systemic tolerability of a 2′O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey , 2014, Inhalation toxicology.

[11]  Christopher E. Hart,et al.  Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  K. Flanigan,et al.  Targeted Exon Skipping to Correct Exon Duplications in the Dystrophin Gene , 2014, Molecular therapy. Nucleic acids.

[13]  S. Takeda,et al.  Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy , 2016, Journal of visualized experiments : JoVE.

[14]  H. Gourabi,et al.  Molecular study of (TG)m(T)n polymorphisms in Iranian males with congenital bilateral absence of the vas deferens. , 2007, Journal of andrology.

[15]  S. Lai,et al.  Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. , 2014, Molecular pharmaceutics.

[16]  B. Roehr.  Fomivirsen approved for CMV retinitis. , 1998, Journal of the International Association of Physicians in AIDS Care.

[17]  J. Moss,et al.  Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium. , 1991, The EMBO journal.

[18]  J. Karras,et al.  Inhaled CD86 Antisense Oligonucleotide Suppresses Pulmonary Inflammation and Airway Hyper-Responsiveness in Allergic Mice , 2007, Journal of Pharmacology and Experimental Therapeutics.

[19]  C. Mann,et al.  Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse , 2003, Nature Medicine.

[20]  W. V. van Roon-Mom,et al.  Antisense oligonucleotides in therapy for neurodegenerative disorders. , 2015, Advanced drug delivery reviews.

[21]  H. Cantiello,et al.  Reversal of cystic fibrosis phenotype in a cultured Delta508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  N. Dias,et al.  Antisense oligonucleotides: basic concepts and mechanisms. , 2002, Molecular cancer therapeutics.

[23]  J C Olsen,et al.  A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. , 1994, The New England journal of medicine.

[24]  D. Corey,et al.  Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs , 2017, Nucleic acids research.

[25]  L. Nogee.  Abnormal expression of surfactant protein C and lung disease. , 2002, American journal of respiratory cell and molecular biology.

[26]  A. Hamvas,et al.  An intronic ABCA3 mutation responsible for respiratory disease , 2012, Pediatric Research.

[27]  F. Goñi,et al.  Lipid-modified oligonucleotide conjugates: Insights into gene silencing, interaction with model membranes and cellular uptake mechanisms. , 2017, Bioorganic & medicinal chemistry.

[28]  Z. Dominski,et al.  Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Weissenbach,et al.  Identification and characterization of a spinal muscular atrophy-determining gene , 1995, Cell.

[30]  M. Stephenson,et al.  Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Karras,et al.  Anti-Inflammatory Activity of Inhaled IL-4 Receptor-α Antisense Oligonucleotide in Mice , 2007 .

[32]  Mallory A. Havens,et al.  Splice-switching antisense oligonucleotides as therapeutic drugs , 2016, Nucleic acids research.

[33]  M. Wood,et al.  Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice , 2016, Nature Communications.

[34]  Elaine Wong,et al.  Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia. , 2014, P & T : a peer-reviewed journal for formulary management.

[35]  R. Finkel,et al.  Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study , 2016, The Lancet.

[36]  L. Nogee,et al.  Surfactant dysfunction. , 2011, Paediatric respiratory reviews.

[37]  A. Bush,et al.  ABCA3 transporter deficiency. , 2012, American journal of respiratory and critical care medicine.

[38]  W. Finkbeiner,et al.  In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N‐of‐1 studies , 2017, Pediatric pulmonology.

[39]  C. Bennett,et al.  Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. , 2015, Advanced drug delivery reviews.

[40]  N. Aronin,et al.  Huntingtin‐lowering strategies in Huntington's disease: Antisense oligonucleotides, small RNAs, and gene editing , 2014, Movement disorders : official journal of the Movement Disorder Society.

[41]  J. Goldblatt,et al.  Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. , 2001, The European respiratory journal.

[42]  S. Russo,et al.  Biosynthesis of Surfactant Protein C (SP-C) , 2002, The Journal of Biological Chemistry.

[43]  J. Whitsett,et al.  Genetic Disorders of Surfactant Dysfunction , 2009, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[44]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[45]  P. Nielsen,et al.  In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid. , 1999, Biochemical and biophysical research communications.

[46]  Xiaoyuan Chen,et al.  Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis , 2008, Nucleic acids research.

[47]  S. Russo,et al.  A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. , 2005, American journal of respiratory cell and molecular biology.

[48]  J. Mendell,et al.  Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History , 2017, Journal of neuromuscular diseases.

[49]  G. Stone,et al.  Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. , 2002, Journal of the American College of Cardiology.

[50]  A. Pêgo,et al.  Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic , 2014, Front. Chem..

[51]  B. Wong,et al.  Multiple exon skipping strategies to by-pass dystrophin mutations , 2012, Neuromuscular Disorders.

[52]  Heinz Schmidli,et al.  Meta-analytic-predictive use of historical variance data for the design and analysis of clinical trials , 2017, Comput. Stat. Data Anal..

[53]  M. Griese.  Pulmonary surfactant in health and human lung diseases: state of the art. , 1999, The European respiratory journal.

[54]  S. Feng,et al.  Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents. , 2015, Nanomedicine.

[55]  J. Karras,et al.  Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice. , 2007, American journal of respiratory cell and molecular biology.

[56]  J. Clancy,et al.  Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. , 2010, The New England journal of medicine.

[57]  A. Hamvas,et al.  Lung Transplantation for Inherited Disorders of Surfactant Metabolism , 2008 .

[58]  Jinglan Zhou,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[59]  D. Paton.  Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy. , 2017, Drugs of today.

[60]  Hugo M. Botelho,et al.  Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides , 2016, Human mutation.

[61]  Christophe Béroud,et al.  Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy , 2007, Human mutation.

[62]  N. Bresolin,et al.  Antisense Oligonucleotide Therapy for the Treatment of C9ORF72 ALS/FTD Diseases , 2014, Molecular Neurobiology.

[63]  N. Schork,et al.  The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? , 2011, Personalized medicine.

[64]  E. Androphy,et al.  Splicing of a Critical Exon of Human Survival Motor Neuron Is Regulated by a Unique Silencer Element Located in the Last Intron , 2006, Molecular and Cellular Biology.

[65]  Helen Donis-Keller,et al.  Site specific enzymatic cleavage of RNA , 1979, Nucleic Acids Res..

[66]  S. Crooke.  RNA directed therapeutics: mechanisms and status , 2013 .

[67]  Atul Gupta,et al.  Genetic disorders of surfactant protein dysfunction: when to consider and how to investigate , 2016, Archives of Disease in Childhood.

[68]  S. Wilton,et al.  Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[69]  Paloma H. Giangrande,et al.  Current progress on aptamer-targeted oligonucleotide therapeutics. , 2013, Therapeutic delivery.

[70]  M. Yeadon,et al.  Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[71]  K. Nagaraju,et al.  Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy , 2007, Expert opinion on biological therapy.

[72]  C. Férec,et al.  Assessing the Disease-Liability of Mutations in CFTR. , 2012, Cold Spring Harbor perspectives in medicine.

[73]  Shuhui Lim,et al.  ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION , 2006, Clinical and experimental pharmacology & physiology.

[74]  R. Juliano,et al.  The delivery of therapeutic oligonucleotides , 2016, Nucleic acids research.

[75]  A. Hamvas.  Evaluation and management of inherited disorders of surfactant metabolism. , 2010, Chinese medical journal.

[76]  M. Knowles,et al.  Correction of Aberrant Splicing of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene by Antisense Oligonucleotides* , 1999, The Journal of Biological Chemistry.

[77]  A. Bush,et al.  Corticosteroids in respiratory diseases in children. , 2012, American journal of respiratory and critical care medicine.

[78]  J. Kreindler.  Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies. , 2010, Pharmacology & therapeutics.

[79]  C. Bennett,et al.  RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. , 2010, Annual review of pharmacology and toxicology.

[80]  R Kole,et al.  Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[81]  J. Whitsett,et al.  Diseases of pulmonary surfactant homeostasis. , 2015, Annual review of pathology.

[82]  Michael J Gait,et al.  A chemical view of oligonucleotides for exon skipping and related drug applications. , 2014, Nucleic acid therapeutics.

[83]  A. Burdick,et al.  Sequence motifs associated with hepatotoxicity of locked nucleic acid—modified antisense oligonucleotides , 2014, Nucleic acids research.

[84]  S. Agrawal,et al.  Pharmacokinetics of Antisense Oligonucleotides , 1995, Clinical pharmacokinetics.

[85]  A. Hamvas,et al.  Genotype-phenotype correlations for infants and children with ABCA3 deficiency. , 2014, American journal of respiratory and critical care medicine.

[86]  C. Stein,et al.  FDA-Approved Oligonucleotide Therapies in 2017. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[87]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[88]  J. Karras,et al.  In Vitro and In Vivo Inhibition of Interleukin (IL)-5–Mediated Eosinopoiesis by Murine IL-5R α Antisense Oligonucleotide , 2001 .

[89]  Stanley T Crooke,et al.  Cellular uptake and trafficking of antisense oligonucleotides , 2017, Nature Biotechnology.

[90]  anastasia. khvorova,et al.  The chemical evolution of oligonucleotide therapies of clinical utility , 2017, Nature Biotechnology.

[91]  M. Lindsay,et al.  Clinical potential of oligonucleotide-based therapeutics in the respiratory system. , 2017, Pharmacology & therapeutics.

[92]  I. Lerer,et al.  Mutation spectrum in Jewish cystic fibrosis patients in Israel: Implication to carrier screening , 2005, American journal of medical genetics. Part A.